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Abstract
Background: MicroRNAs (miRNAs) are important small non-coding RNA molecules that regulate gene expression
in cellular processes related to the pathogenesis of cancer. Genetic variation in miRNA genes could impact their
synthesis and cellular effects and single nucleotide polymorphisms (SNPs) are one example of genetic variants
studied in relation to breast cancer. Studies aimed at identifying miRNA SNPs (miR-SNPs) associated with breast
malignancies could lead towards further understanding of the disease and to develop clinical applications for early
diagnosis and treatment.
Methods: We genotyped a panel of 24 miR-SNPs using multiplex PCR and chip-based matrix assisted laser
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) analysis in two Caucasian breast
cancer case control populations (Primary population: 173 cases and 187 controls and secondary population:
679 cases and 301 controls). Association to breast cancer susceptibility was determined using chi-square (X2)
and odds ratio (OR) analysis.
Results: Statistical analysis showed six miR-SNPs to be non-polymorphic and twelve of our selected miR-SNPs
to have no association with breast cancer risk. However, we were able to show association between rs353291
(located in MIR145) and the risk of developing breast cancer in two independent case control cohorts (p = 0.041 and
p = 0.023).
Conclusions: Our study is the first to report an association between a miR-SNP in MIR145 and breast cancer risk in
individuals of Caucasian background. This finding requires further validation through genotyping of larger cohorts or
in individuals of different ethnicities to determine the potential significance of this finding as well as studies aimed to
determine functional significance.
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Background
MicroRNAs (miRNAs) are small non-coding single
stranded RNA molecules (21 – 25 nucleotides) involved
in negative regulation of gene expression [1, 2]. miRNAs
are transcribed from long microRNA primary transcripts
(pri-miRNAs) containing miRNA precursors (pre-miRNA,
stem-loop molecules of 55 – 70 nucleotides). Pre-miRNAs
are usually generated via the canonical pathway [3], where
pri-miRNAs are cleaved by the complex formed by the
nuclear ribonuclease (RNase) III DROSHA and the RNA-
binding protein DCGR8 (DiGeorge syndrome critical
region gene 8) [4]. Following transport to the cytoplasm
by XPO5 (exportin5) and the nuclear protein ran-GTP,
they are processed by DICER1 [5, 6]. The resultant duplex
molecule contains both a single-stranded mature miRNA
sequence and a complementary miRNA* strand which is
released and degraded while the mature miRNA is loaded
into the RNA-induced silencing complex (RISC) and
merged into the Argonaute/EIFC2C (Ago) proteins [7, 8].
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Each miRNA may bind to up to 200 gene targets and mul-
tiple binding sites for different miRNAs, making a highly
complex web of interactions affecting a variety of bio-
logical pathways [9, 10].
miRNAs are very likely to play an important role in
cancer biology due to their role in the regulation of
important cellular processes including growth, differenti-
ation and cell survival [11–16]. Several mechanisms re-
sult in changes in miRNA synthesis and expression in
relation to cancer including: point mutations in miRNA
and mRNA sequences, loss or mutation in the promoter
regions for specific miRNA clusters, epigenetic changes
and alterations in pathway related to dsRBD proteins
[17–19]. Single nucleotide polymorphisms (SNPs) in
miRNA genes (miR-SNPs) are one example of point
mutation (albeit one occurring in the past) that could
affect miRNA function in one of three possible ways: al-
tering transcription of the primary miRNA transcript;
processing of the pri-miRNA and pre-miRNA and;
through their effects on modulation of miRNA-mRNA
interactions [20–23]. As a result miR-SNPs have been
associated with different types of cancer, including
chronic lymphocytic leukaemia, gastric, lung and thyroid
carcinoma [24–27].
Breast cancer is the second most commonly diagnosed
cancer worldwide (1.67 million new cases, 25%) and the
most common type of cancer for women in developed
countries (793,684 new cases, 28%) [28]. Recent evidence
suggests a role for miR-SNPs in breast cancer suscepti-
bility including work by Hu et al. where the presence of
mutant alleles of MIR196A2 rs11614913 and MIR499A
rs3746444 significantly increased breast cancer risk in
Chinese women [29]. However in genetic association
analysis of Caucasian populations and functional studies
in breast cancer cell lines performed by Hoffman et al.
the presence of SNP in MIR196A2 rs11614913 was sig-
nificantly associated with reduced risk of breast cancer,
as well as less efficient processing of MIR196A2 and
reduced capacity to regulate target genes, indicating
additional factors may be at work in this SNP’s effect on
breast cancer [30]. Additionally, Kontorovich et al. found
2 SNPs, rs6505162 and rs895819 located in MIR423 and
MIR27A precursors respectively, to be significantly
associated with decreased risk of breast cancer in
BRCA2 mutation carriers from a Jewish population [31].
rs895819 was also significantly associated with reduced
risk of developing breast cancer in families with a history
of non-BRCA related breast cancer in a later study per-
formed by Yang et al [32]. Finally rs2910164, a miR-SNP
located in the 3p strand of MIR146A, was found to be
associated with a younger age of diagnosis in familial
breast cancer for BRCA1 mutation carriers [33].
In this study, we have investigated a panel of miR-
SNPs present in miRNA genes previously identified to
be involved in the pathophysiological mechanisms of
breast cancer. Our initial selection included 24 variants
Fig. 1 MicroRNA SNP (miR-SNP) selection algorithm using the Human miRNA Disease Database (HMDD). This flow chart shows workflow for
selection of preliminary miR-SNPs included in genotyping study. Abbreviations: dbSNP, single nucleotide polymorphism database; MAF, minor
allele frequency; miRNA, microRNA; NCBI National Center for Biotechnology Information; SNP, Single nucleotide polymorphisms
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Table 1 Selected features from the Human miRNA disease database (HMDD) included in present study
Selected diseases and/or pathological features related to breast cancer
miRNA-disease association
dataset
Human miRNA genes in dataset 1. Adenocarcinoma 5. Squamous Cell Carcinoma
503 2. Breast Neoplasms 6. Neoplasms
3. Carcinoma 7. Germ cell and embryonal neoplasm
Human Diseases in dataset 4. Ductal breast carcinoma 8. Squamous cell neoplasms
396
Selected biological and/or cellular function in relation to Cancer
miRNA function dataset Human miRNA genes in dataset
503 1. Activation of caspases
cascade
13. Cell proliferation
2. Akt pathway 14. Chemosensitivity of tumour cells
3. Angiogenesis 15. Chemotaxis
4. Anti-cell proliferation 16. Chromatin remodelling
5. Apoptosis 17. DNA Repair
6. Cell cycle related 18. Epithelial-mesenchymal transition
Biological and cellular functions in
dataset
7. Cell death 19. Human embryonic stem cell (hESC)
regulation
8. Cell differentiation 20 Immune response
9. Cell division 21. Immune system
10. Cell fate determination 22. Inflammation
43 11. Cell motility 23 miRNA tumour suppressors
12. Cell proliferation 24. Onco-miRNAs
Table 2 List of the miRNA SNPs included in multiplex primer design using the MassARRAY® Assay Design Suite v1.0 software
(SEQUENOM Inc., San Diego, CA, USA)
miRNA Locus Location SNPs in gene
region
MAF Location SNPs near
3' end
MAF Location SNPs near
5' end
MAF Location
MIR210 11p15.5 568,089 - 568,198 rs1062099 0.1877 567,627 rs7395206 0.5000 568,211
rs10902173 0.4835 570,072
MIR34A 1p36.22 9,211,727 - 9,211,836 rs35301225 NA 9,211,802 rs77585961 0.0247 9,211,468
MIR155 21q21.3 26,946,292 - 26,946,356 rs2829801 0.4707 26,944,305 rs1547354 0.0810 26,946,709
MIR221 Xp11.3 45,605,585 - 45,605,694 rs7050391 0.0133 45,605,273 rs2858061 0.4352 45,606,132
rs2858060 0.4991 45,607,008
rs2858059 0.4786 45,607,190
MIR222 Xp11.3 45,606,421 - 45,606,530 rs2858061 0.4352 45,606,132 rs2858060 0.4991 45,607,008
rs2858059 0.4786 45,607,190
MIR21 17q23.1 57,918,627 - 57,918,698 rs112394324 0.0032 57,918,251 rs1292037 0.2440 57918908
rs3851812 0.0371 57,918,370 rs13137 0.2440 57919031
MIRLET7A1 9q22.32 96,938,239 - 96,938,318 rs10761322 0.4588 96,937,478
rs10739971 0.2601 96,937,680
MIRLET7A2 11q24.1 122,017,230 - 122,017,301 rs629367 0.1451 122,017,014 rs1143770 0.4867 122,017,598
rs562052 0.3265 122,018,550
rs693120 0.3265 122,019,011
MIR145 5q32 148,810,209 - 148,810,296 rs55945735 0.2010 148,809,158 rs353291 0.3324 148,810,746
rs73798217 0.0545 148,809,918
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located in 10 miRNA genes or in close proximity which
were genotyped using multiplex PCR and matrix-assisted
laser desorption/ionisation time-of-flight mass spectrom-
etry (MALDI-TOF MS) analysis. Genotyping results of the
19 miR-SNPs successfully genotyped and included in this
study identified six previously reported microRNA SNPs
as non-polymorphic. From the remaining polymorphisms
twelve miR-SNPs showed no significant differences be-
tween cases and controls and one variant in MIR145
was identified to be associated with breast cancer sus-
ceptibility in both of our Australian Caucasian breast
cancer case-control populations.
Methods
Study populations
Two independent Australian Caucasian breast cancer
case populations were available for our study: The
Genomics Research Centre Breast Cancer (GRC-BC)
population and part of the Griffith University-Cancer
Council Queensland Breast Cancer Biobank (GU-CCQ
BB). We conducted single nucleotide polymorphism
genotyping in the GRC-BC population initially. This
consisted of DNA samples from 173 breast cancer
patients from South East Queensland and DNA samples
from 187 healthy age and sex matched females with no
personal and/or familial history of breast, ovarian or any
other type of cancer collected at the Genomics Research
Centre Clinic, Southport, with research approved by
Griffith University’s Human Ethics Committee (Ap-
proval: MSC/07/08/HREC and PSY/01/11/HREC) and
the Queensland University of Technology Human Re-
search Ethics Committee (Approval: 1400000104). Breast
cancer samples comprised prevalent breast cancer cases
diagnosed previous to their inclusion in this study. All par-
ticipants supplied informed written consent. Average age
of test population was 57.52 years and 57 years for cases
and controls respectively.
Further validation of genotyping results was performed
on a subset of the GU-CCQ BB population. 679 DNA
samples from breast cancer patients residing in Queens-
land with a diagnosis of invasive breast cancer confirmed
histologically were used to validate genotyping of miR-
SNPs. Patient samples had been collected by the Gen-
omics Research Centre in collaboration with the Cancer
Council of Queensland as part of a 5-year population-
based longitudinal study since January 2010. Patients
Table 3 Primer sequences for the miRNA SNPs included in genotyping study using multiplex PCR reaction and MALDI-TOF MS
SNP Forward primer sequence Reverse primer sequence iPLEX® (Extension) primer sequence
rs2829801 ACGTTGGATGTTCCCACTCAGGCATATAGC ACGTTGGATGTGGAGTCTATGTCCACTTCC TGGGCTAAGCAACCA
rs7395206 ACGTTGGATGTCGGACGCCCAAGTTGGAG ACGTTGGATGTCACACGCACAGTGGGTCT GGTGGGCGGGCGGAG
rs73798217 ACGTTGGATGACTGGAGGTTATCAGAGAGG ACGTTGGATGATGTGTATTCCCCAGTCTCC ACCATTCAGTTCCTAGC
rs353291 ACGTTGGATGGTAGAGATGCCACAAGAGGG ACGTTGGATGAAACCTTAAGTCTTCGTTCG GGTTGTTCTCTGGCTGC
rs55945735 ACGTTGGATGGGTCTCAAACTCCTGACTTC ACGTTGGATGCTGCATCTGAGCACTTCAAG TGATGCCTGGCGGGGCG
rs10902173 ACGTTGGATGTCACAGGCACCTTTTCTCAG ACGTTGGATGGAAGCCTGGGTATTAGGATG ACCTTTTCTCAGCATCTG
rs112394324 ACGTTGGATGACTGGAGAGAGAAATTACCC ACGTTGGATGGTTGAAACCAGAGTACATGC CAGATACGACAGAGTGTG
rs1292037 ACGTTGGATGTACAGCTAGAAAAGTCCCTG ACGTTGGATGGGAGGGAGGATTTTATGGAG AACCTTTTCAAAACCCACA
rs562052 ACGTTGGATGCTCCAGGCTAGTGGAATAAC ACGTTGGATGCTACTGCACTGATCGTGTTC CAGATTCAAATGCCATAGCA
rs2858059 ACGTTGGATGCAGTAAGTATTTCTGGGGTG ACGTTGGATGCTCCCATGATACAATGAAGG TGGGGTGGATAAATGAATAG
rs1062099 ACGTTGGATGGACCCGGTCCTGATTTTAAC ACGTTGGATGTGTGTTTCTGCCGCTTCAGT TTTAACAGTAGACTTGAGAAG
rs10739971 ACGTTGGATGCCTAATAAGACCACTTAGTGT ACGTTGGATGATGCACTAACATACAACGAG CCACCTACTCATTTATCCCATG
rs2858060 ACGTTGGATGACTGTATTATCCTCAGTTC ACGTTGGATGACTTGGGTAATCTAGCAATG GTATTATCCTCAGTTCGTAACA
rs2858061 ACGTTGGATGGCTTTCAATACTACAAGGG ACGTTGGATGAATGATACCTTTCATAGGGG GTAAAACAAAAACAGGTAAGAG
rs35301225 ACGTTGGATGGGCAGTATACTTGCTGATTG ACGTTGGATGGCTGTGAGTGTTTCTTTGGC GGATTATTGCTCACAACAACCAG
rs1547354 ACGTTGGATGTTGCAGGTTTTGGCTTGTTC ACGTTGGATGGGAGGTTAGTAGTCCTTCTA TTTGATTCAACTGTTAGAAATGTG
rs13137 ACGTTGGATGAGGTGAAAGAGATGAACCAC ACGTTGGATGAAAGCATTCCCAAAATGCTC TCCCAAAATGCTCTATTTTAGATAG
rs10761322 ACGTTGGATGGCTTTTGGTTACTAAATCAC ACGTTGGATGCTTCATATTTAGGAGGTAGC GGCATATTTAGGAGGTAGCTACTAC
rs693120 ACGTTGGATGGTAGATGGCACATATAGAAA ACGTTGGATGCATCCCTTAACTGTAAGTTC GATTGTCAAATGAAAAGAAGAATAT
rs1143770 ACGTTGGATGCTGAACAATTTAATGCCTTC ACGTTGGATGTTCAGTTTTACCAGAGGAAC CCCCCATGCCTTCTGATATCTGTTGA
rs77585961 ACGTTGGATGGTTTCCTTCTCTGCAAGACG ACGTTGGATGCACTTACTATGCAGGAAGGC CCTACATGATGTAATACACTTACAATA
rs7050391 ACGTTGGATGGTAAGGCAGTATGATTAGGC ACGTTGGATGGCCTCAACTGTCAAAGATTG TGTTCATAATTATTATCAGAAGGCATA
rs3851812 ACGTTGGATGTTTTCCTCCCAAGCAAAAC ACGTTGGATGTTCTTGCCGTTCTGTAAGTG GGTGGAAGTGTTTTATTCTTAGTGTGA
rs629367 ACGTTGGATGTATGCAGCATTTTTGTGAC ACGTTGGATGATTCTGTTTCCTCGGGTTAG GGGGTCAGCATTTTTGTGACAATGGACA
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included in this study were between 33 and 80 years of
age, with an average age of 60.16 and they were screened
for personal and/or familial history of breast, ovarian or
any other type of cancer. Control population for the
GU-CCQ BB was established from 2 sources: The con-
trol group for this cohort was comprised of genotyping
result data taken from 201 healthy females belonging to
the phase 1 European population from the 1000Ge-
nomes project. Efforts were made to select a subgroup
of individuals that were comparable to the case group in
terms of age, ethnicity and sex [34].
Genomic DNA sample preparation from whole human
blood
Genomic DNA was extracted from whole blood samples
using a modified salting out method described previ-
ously [35, 36]. DNA samples were evaluated by spectro-
photometry using the Thermo Scientific NanoDrop™
8000 UV-Vis Spectrophotometer (Thermo Fisher Scien-
tific Inc., Wilmington, DE. USA) to determine DNA
yield and 260/280 ratios [37–39]. Samples with a reading
below 1.7 for their 260/280 ratio were purified using an
ethanol precipitation protocol to guarantee DNA sample
purity [40].
miRNA SNP selection
Figure 1 shows the selection process we followed to
determine miRNA SNPs (miR-SNPs) that could be
included in our study. Two datasets, “The whole
miRNA-disease association data” and “The miRNA func-
tion set data” from the human miRNA disease database
(HMMDD) created by Lu et al. [41] and updated in
January 2012, were used to select 8 diseases and/or
pathological characteristics and 24 biological and/or
cellular functions related to breast cancer (See Table 1).
As shown in Fig. 1, we picked the 50 miRNA genes from
each dataset that were present in the majority of selected
features for inclusion in the following steps. This list was
narrowed down to the 25 miRNA genes on each dataset
with the strongest evidence in order to maximise the po-
tential for identification of biologically relevant mole-
cules using two main criteria: miRNAs involved in the
largest number of selected features from each group
followed by a literature search to confirm the number of
publications showing significant relationships to cancer
biology or the possession of known functional effects of
polymorphisms within the miRNA itself. Following this,
we chose 10 miRNA genes from the 25 genes on both
lists, again prioritising by number of functions and pub-
lications, and conducted a search to identify SNPs using
both dbSNP database from The National Center for Bio-
technology Information (NCBI) [42] and 1000 Genomes
project browser [43]. Final selection of SNPs was done
using this algorithm: All microRNA-SNPs located inside
the pre-miRNA gene were automatically included in the
SNP selection. However, SNPs located outside of the
pre-miRNA gene were assessed using the following cri-
teria: miR-SNPs located up to 500bp upstream or down-
stream from pre-miRNA were automatically included in
the SNP selection. On the other hand, SNPs located
more than 500bp from the 3’ or 5’ end were chosen only
if they had a previously reported minor allele frequency
Table 5 Allele and genotype frequencies for miRNA SNPs in MIR221 and MIR222 from the GRC-BC Population
rs2858061 rs2858060
Allele Genotype Allele Genotype
G (%) C (%) p-value GG (%) CG (%) CC (%) p-value C (%) G (%) p-value CC (%) GC (%) GG (%) p-value
Control 323 (87.8) 45 (12.2) 0.43 142 (77.2) 39 (21.2) 3 (1.6) 0.38 219 (69.3) 97 (30.7) 0.75 81 (51.3) 57 (36.1) 20 (12.7) 0.35
Cases 295 (85.8) 49 (14.2) 130 (75.6) 35 (20.3) 7 (4.1) 218 (68.1) 102 (31.9) 74 (46.3) 70 (43.8) 16 (10.0)
Hapmap
(%)
86.2 13.8 80.2 12.4 7.4 72.8 27.2 62.3 20.6 17.2
Table 4 Allele and genotype frequencies for miRNA SNPs in MIR210 obtained from the GRC-BC population
rs1062099 rs10902173
Allele Genotype Allele Genotype
G (%) C (%) p-
value
GG (%) CG (%) CC
(%)
p-
value
C (%) T (%) p-
value
CC (%) TC (%) TT (%) p-
value
Control 300 (83.3) 60
(16.7)
0.36 126
(70.0)
48
(26.7)
6 (3.3) 0.61 203
(59.0)
141
(41.0)
0.93 63
(36.6)
90
(49.5)
29
(15.9)
0.64
Cases 263 (80.7) 63
(19.3)
106
(65.0)
51
(31.3)
6 (3.7) 216
(59.3)
148
(40.7)
63
(34.6)
77
(44.8)
32
(18.6)
Hapmap
(%)
81.7 18.3 66.8 29.8 3.4 60.4 39.6 34.8 51.2 14.0
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higher than 5% in Caucasian populations. As a result 56
microRNA SNPs were identified in this preliminary se-
lection (Data not shown) (See Fig. 1).
Primer design
Using the MassARRAY® Assay Design Suite v1.0 soft-
ware (SEQUENOM Inc., San Diego, CA, USA) we were
able to create a single multiplex PCR genotyping assay
containing 24 miR-SNPs from our preliminary selection
(See Table 2). We designed forward and reverse PCR
primers and one iPLEX® (extension) primer and verified
that the mass of extension primers differed by at least 30
Da among different SNPs and by 5 Da between alterna-
tive alleles of the same marker to achieve successful
marker and allele identification by mass spectrometry
analysis. Primers were manufactured by Integrated DNA
Technologies (IDT®) Pte. Ltd. (Baulkham Hills, NSW
2153, Australia) and primer information is shown in
Table 3.
Primary multiplex PCR
Genotyping was undertaken following the iPLEX™ GOLD
genotyping protocol using the iPLEX® Gold Reagent Kit
(SEQUENOM Inc., San Diego, CA, USA). Primer exten-
sion reactions were performed according to the instruc-
tions for the SEQUENOM linear adjustment method
included in the iPLEX™ GOLD genotyping protocol
(SEQUENOM Inc., San Diego, CA, USA). All reactions
were performed using Applied Biosystems® MicroAmp®
EnduraPlate™ Optical 96-Well Clear Reaction Plates with
Barcode (Life Technologies Australia Pty Ltd., Mulgrave,
VIC, Australia) and an Applied Biosystems® Veriti® 96-
Well Thermal Cycler (Life Technologies Australia Pty
Ltd., Mulgrave, VIC, Australia).
MALDI-TOF MS analysis and data analysis
A total of 12-16 nl of each iPLEX® reaction product
were transferred onto a SpectroCHIP® II G96 (SEQUE-
NOM Inc., San Diego, CA, USA) using SEQUENOM®
MassARRAY® Nanodispenser (SEQUENOM Inc., San
Diego, CA, USA). SpectroCHIP® analysis was carried
out by SEQUENOM® MassArray® Analyzer 4 and the
SpectroAcquire software Version 4.0 (SEQUENOM
Inc., San Diego, CA, USA). Finally data analysis for
genotype determination was done using the MassAR-
RAY® Typer software version 4.0 (SEQUENOM Inc.,
San Diego, CA, USA). In order to confirm the geno-
types obtained, randomly selected samples (5 each for
case and control cohorts) from each genotype (n = 240)
were validated by Sanger Sequencing to ensure accur-
acy of genotyping results. In all cases, the Sanger Se-
quencing confirmed the genotyping obtained using
MassARRAY.
Statistical analysis
Statistical analysis of genotypes and alleles was con-
ducted using Plink software version 1.07 (http://
pngu.mgh.harvard.edu/purcell/plink/) [44]. The α for
p-values was set at 0.05 to determine statistically sig-
nificant association with breast cancer. Genotype and
Table 6 Allele and genotype frequencies for miRNA SNPs in MIR21 obtained from the GRC-BC population
rs1292037 rs13137
Allele Genotype Allele Genotype
A (%) G (%) p-
value
AA (%) GA (%) GG
(%)
p-
value
T (%) A (%) p-
value
TT (%) AT (%) AA
(%)
p-
value
Control 300
(80.6)
72
(19.4)
0.86 122
(65.6%)
56
(30.1)
8 (4.3) 0.95 299
(80.8)
71
(19.2)
0.85 122
(65.9)
55
(29.7)
8 (4.3) 0.94
Cases 274
(80.1)
68
(19.9)
110 (64.3) 54
(31.6)
7 (4.1) 276
(80.2)
68
(19.8)
111
(64.5)
54
(31.4)
7 (4.1)
Hapmap
(%)
81.0 19.0 65.4 31.1 3.4 81.0 19.0 65.4 31.1 3.4
Table 7 Allele and genotype frequencies for miRNA SNPs in MIRLET7A1 obtained from the GRC-BC cohort
rs10761322 rs10739971
Allele Genotype Allele Genotype
T (%) C (%) p-
value
TT (%) TC (%) CC (%) p-
value
G (%) A (%) p-
value
GG (%) AG (%) AA (%) p-
value
Control 225
(61.8)
139
(38.2)
0.73 76
(41.8)
73
(40.1)
33
(18.1)
0.08 243
(67.5)
117
(32.5)
0.39 89
(49.4)
65
(36.1)
26
(14.4)
0.36
Cases 207
(60.5)
135
(39.5)
59
(34.5)
89
(52.0)
23
(13.5)
223
(64.5)
123
(35.5)
74
(42.8)
75
(43.4)
24
(13.9)
Hapmap
(%)
61.9 38.1 40.9 42.0 17.2 68.1 31.9 46.4 43.3 10.3
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Table 8 Allele and genotype frequencies for miRNA SNPs in MIRLET7A2 obtained from the GRC-BC population
rs629367 rs562052 rs693120
Allele Genotype Allele Genotype Allele Genotype
A (%) C (%) p-
value
AA (%) CA (%) CC
(%)
p-
value
G (%) A (%) p-
value
GG (%) AG (%) AA (%) p-
value
G (%) A (%) p-
value
GG (%) AG (%) AA (%) p-
value
Control 302
(82.5)
64
(17.5)
0.72 125
(68.3)
52
(28.4)
6
(3.3)
0.88 242
(65.4)
128
(34.6)
0.76 81
(43.8)
80
(43.2)
24
(13.0)
0.57 230
(67.3)
112
(32.7)
0.77 82
(48.0)
66
(38.6)
23
(13.5)
0.21
Cases 289
(83.5)
57
(16.5)
122
(70.5)
45
(26.0)
6
(3.5)
230
(66.5)
116
(33.5)
74
(42.8)
82
(47.4)
17 (9.8) 225
(66.2)
115
(33.8)
72
(42.4)
81
(47.6)
17
(10.0)
Hapmap
(%)
84.6 15.4 75.4 18.5 6.2 68.1 31.9 46.2 43.8 10.0 68.1 31.9 46.2 43.8 10.0
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allele frequencies for each miRNA SNP in our case
and control populations were established and we
used Hardy-Weinberg equilibrium (HWE) to evaluate
deviation between observed and expected frequencies
for identification of unexpected population or geno-
typing biases [45, 46]. We performed Chi square
analysis to evaluate differences in genotype and allele
frequencies between cases and controls for each
independent population [47]. Finally we calculated
odds ratio (OR) and obtained 95% confidence inter-
val (CI) 95% to assess disease risk.
Results and discussion
MicroRNAs are some of the small non-coding RNA
molecules responsible for gene regulation at the
translational level. They require a very complex series
of nuclear and cytoplasmic processes for their synthe-
sis and to achieve their functional effects on genes
involved in key cellular functions like replication and
cell differentiation [7, 10, 13]. As a result they are
likely to play a role in the development and progres-
sion of cancer due to the important biological mecha-
nisms they regulate [12, 15, 16]. They have been
shown to have different roles in various types of
cancer including breast cancer [18, 24]. Breast cancer
is a cause for concern since recent reports by the
IARC show it has very high incidence and mortality
rates around the world [28]. Analysis of single nu-
cleotide polymorphisms in well-defined case control
cohorts has provided information on miR-SNPs in-
volved in the pathophysiology of different types of
cancer including breast cancer [25–27, 29–33].
Therefore we selected a panel of 24 miR-SNPs related
to 9 miRNA genes previously identified to play a role
in breast cancer to genotype in our Australian Cauca-
sian breast cancer case control populations. Genotyp-
ing of our selected miRNA variants in the GRC-BC
cohort showed six of them to be non-polymorphic
(rs73798217, rs112394324, rs35301225, rs1547354,
rs7050391 and rs3851812) and another five of the
chosen miR-SNPs failed to successfully deliver geno-
types (rs2829801, rs7395206, rs2858059, rs1143770
and rs77585961).
On the other hand, genotype and allele frequencies of
the remaining 13 miR-SNPs in the GRC-BC cases and
controls showed these to be closely similar to those
found in Hapmap for Caucasian populations and they
were also in Hardy Weinberg Equilibrium (HWE) (p >
0.05). Ultimately, however, chi-square analysis of geno-
typing results of 12 SNPs located in relation to seven
miRNAs (MIR210, MIR221, MIR222, MIR21, MIRLET7A1,
MIRLET7A2 and MIR145) showed no significant differ-
ences for genotype and allele frequencies between cases
and controls in our GRC-BC population (See Tables 4, 5, 6,
7, 8 and 9).
In contrast, we were able to determine significant
differences at the allelic level for rs353291 after chi-
square analysis in our GRC-BC cohort (p = 0.041)
although no significant difference in genotype fre-
quencies (p = 0.09) (See Table 10). We then pro-
ceeded to genotype this SNP in the GU-CCQ BB
population and we also found the genotype and al-
lele frequencies closely matched Hapmap frequencies
for Caucasian populations and cases and controls
were in HWE. Statistical analysis of genotyping in
our replication population showed similar findings to
those obtained in the GRB-BC cohort shown in
Table 10. We were able to find significant differences
in allele frequencies between cases and controls in
the GU-CCQ BB population (p = 0.006) and also sta-
tistically significant differences at the genotype level
(p = 0.02). Finally we calculated odds ratios for alleles
in the GRC-BC and GU-CCQ BB populations to be
1.37 (CI 95%: 1.01–1.84) and 1.31 (CI 95%: 1.04–
1.70) respectively, suggesting the presence of the C
allele at this locus increases the risk of developing
breast cancer. However it should be noted that if we
consider multiple testing, our finding for the analysis
of allele frequencies for both populations for this
variant is not significant if we determine Bonferroni
correction of the α for p-value to be 2.08 x 10−3.
However these results are still potentially interesting
particularly considering the similarity of allelic sig-
nificance in both independent case-control cohorts
and point to the need for further genotyping in ex-
tended populations.
miR-SNP rs353291 is located 450 bp upstream from
the MIR145 gene, inside the miRNA 143 host gene
transcript, in the long arm of chromosome 5 region
32 at position 148,810,746. To the best of our
Table 9 Allele and genotype frequencies for rs55945735 located in MIR145 obtained from the GRC-BC population
rs55945735
Allele Genotype
A (%) G (%) p-value AA (%) GA (%) GG (%) p-value
Control 193 (59.9) 129 (40.1) 0.29 61 (37.9) 71 (44.1) 29 (18.0) 0.58
Cases 182 (64.1) 102 (35.9) 60 (42.3) 62 (43.7) 20 (14.1)
Hapmap (%) 62.8 37.2 38.3 49.1 12.7
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knowledge there are no previous association studies
in relation to this miR-SNP and breast cancer risk in
Caucasians or any populations of other ethnicities.
However, MIR145 has been previously reported to
play a role in cancer biogenesis and progression.
Downregulation of MIR145 is a common finding pre-
viously reported in colorectal [48, 49], bladder [50],
lung [51, 52] and oesophageal [53] cancers possibly
leading to poor prognosis. Similarly, it has also been
found to have a tumour suppressor role in breast tis-
sue particularly in the myoepithelial/basal cell com-
partment and it is found to be downregulated in
breast cancer tissue samples [54–56]. Research using
breast cancer cell lines showed it regulates genes in-
volved in modulation of apoptosis [57, 58]. Finally
downregulation of MIR145 has been associated with a
more aggressive behaviour of breast malignancies
based on results performed in both breast cancer cell
line and tissue samples [59, 60]. However the molecu-
lar mechanisms leading to decreased expression of
MIR145 still remain unknown and our finding could
potentially help to provide further knowledge on
these mechanisms through further functional valid-
ation on breast cancer cell culture and/or animal/
models. It is also possible that rs353291 is linked to a
different nearby SNP not considered in this research
that may have direct functional effects on MIR145, so
additional sequencing/genotyping studies may need to
be performed prior to functional assessment of the
link between rs353291 and breast cancer.
Conclusions
We were able to determine that the presence of a
polymorphism in miR-SNP rs353291 is associated
with an increased risk of developing breast cancer
based on our findings. To the best of our knowledge,
this is the first report on breast cancer risk associ-
ation for this variant in individuals of Caucasian
background. This finding could potentially explain
the previously described role that MIR145 plays in
breast cancer documented in the literature, but it re-
quires confirmation via functional studies using cell
culture or animal models. It also requires further valid-
ation on larger Caucasian population as well as in cohorts
of individuals with different ethnical backgrounds before
it can be translated into clinical applications used in breast
cancer diagnosis or treatment.
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